Publications

Type 2 diabetes mellitus represented a global metabolic crisis characterized by progressive beta cell dysfunction, insulin resistance, and chronic hyperglycemia. Traditional incretin-based therapies targeting glucagon-like peptide 1 (GLP-1) receptors have demonstrated glycemic efficacy, yet residual metabolic dysfunction persists in many patients. Glucose-dependent insulinotropic polypeptide (GIP), the other major incretin hormone, has emerged as a complementary therapeutic target with distinct metabolic actions. This review examined the biochemical mechanisms, clinical efficacy, and metabolic benefits of dual GIP/GLP-1 receptor agonists in type 2 diabetes management, with emphasis on glycemic control, weight reduction, and cardiometabolic outcomes. A comprehensive synthesis of preclinical mechanistic studies, phase 2 and 3 clinical trials, and comparative effectiveness research was conducted to evaluate dual agonist pharmacology and therapeutic impact. Dual receptor agonists demonstrated superior glycemic control compared to selective GLP-1 agonists, with hemoglobin A1c reductions exceeding 2.0 percent and substantial weight loss of 10 to 15 percent of body weight. The synergistic effects arose from complementary actions on insulin secretion, glucagon suppression, energy expenditure, and adipose tissue metabolism. Enhanced beta cell function, improved insulin sensitivity, and favorable effects on hepatic steatosis and lipid profiles contribute to comprehensive metabolic improvement. Dual GIP/GLP-1 receptor agonists represented a paradigm advancement in diabetes pharmacotherapy, offering superior efficacy through integrated incretin signaling and addressing multiple pathophysiological defects underlying type 2 diabetes.